An observational study on monoclonal antibodies against calcitonin‐gene‐related peptide and its receptor

Key Points

Key points are not available for this paper at this time.

Abstract

The present study on a real-world sample confirms the beneficial effect of both anti-CGRP and anti-CGRP-R mAbs, with a more favorable outcome for anti-CGRP antibodies.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Cola et al. (Wed,) studied this question.

synapsesocial.com/papers/69d709f041375cf86eed8f49 https://doi.org/https://doi.org/10.1111/ene.15761

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A second trigeminal <scp>CGRP</scp> receptor: function and expression of the <scp>AMY</scp> <sub>1</sub> receptor2015 · 186 citations
2Endosomal signaling of the receptor for calcitonin gene-related peptide mediates pain transmission2017 · 181 citations
3Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis2021 · 43 citations
4Evaluation of Galcanezumab for the Prevention of Episodic Migraine2018 · 566 citations
5Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial2018 · 557 citations

Bookmark

View Full Paper